Fulvestrant: Clinical Trials

489 trials of Fulvestrant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

165 completed, 85 recruiting, 72 active not recruiting, 67 terminated. 281 Phase 2, 147 Phase 1, 84 Phase 3, 9 Phase 4, 4 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2281Completed 92, Recruiting 51, Terminated 42, Active not recruiting 36, Unknown 33, Not yet recruiting 15, Withdrawn 12
Phase 1147Completed 43, Recruiting 38, Active not recruiting 17, Terminated 16, Withdrawn 12, Unknown 11, Not yet recruiting 10
Phase 384Active not recruiting 26, Completed 23, Recruiting 12, Terminated 9, Unknown 9, Not yet recruiting 5
Phase 49Completed 4, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1
Not applicable4Unknown 3, Recruiting 1
Early Phase 12Completed 1, Withdrawn 1

Follow Fulvestrant: new trials by email Literature Review of Fulvestrant trials Research Report on Fulvestrant

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Phase 2Not yet recruitingUniversity of California, San Diego1502027-07-012026-07-27
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Phase 2Not yet recruitingNovartis Pharmaceuticals512026-12-152026-09-18
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer
Phase 1Not yet recruitingGenentech, Inc.1652026-12-152026-11-05
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Inavolisib, Fulvestrant, Palbociclib - Breast Cancer, Diabetes Type II
Phase 2RecruitingHoffmann-La Roche402026-11-302026-11-13
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer
Phase 1RecruitingPrelude Therapeutics Incorporated2422026-11-162026-11-12
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Phase 1Not yet recruitingPfizer2682026-11-092026-10-28
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
Fulvestrant, Pyrotinib, Dalpiciclib - Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer
Phase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2262026-11-012026-10-23
KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer
KC1086, Fulvestrant, Everolimus (10 mg QD) - HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase 2Not yet recruitingBeijing Konruns Pharmaceutical Co., Ltd.1682026-11-012026-11-16
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
NSAI + CDK4/6i, NSAI + CDK4/6i + Capivasertib, Fulvestrant + CDK4/6i + Capivasertib - HR Positive/HER-2 Negative Breast Cancer
Phase 3Not yet recruitingSWOG Cancer Research Network10842026-10-302026-09-03
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
Phase 2Not yet recruitingMedSIR252026-10-042026-06-01
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
Fulvestrant, Anastrozole (ARIMIDEX™) - Inguinal Hernia Unilateral, Inguinal Hernia Without Obstruction or Gangrene
Phase 1RecruitingNorthwestern University302026-10-022026-11-16
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
K-1728, Fulvestrant, Palbociclib - Breast Neoplasms, Solid Tumors
Phase 1 / Phase 2Not yet recruitingKymaThera, Inc.1102026-10-012026-10-06
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2402026-10-012026-07-21
JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
JYP0035 plus Fulvestrant, JYP0035 placebo plus Fulvestrant - Breast Cancer
Phase 3Not yet recruitingChengdu JOYO pharma Co., Ltd.1712026-09-302026-08-25
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant - Metastatic (Stage IV) Melanoma
Phase 2Not yet recruitingUNICANCER512026-09-182026-08-03
Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer
Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital312026-09-012026-10-19
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
AL58805, AL8326, Eribulin - Endometrial Neoplasms, Soft Tissue Sarcoma (STS)
Phase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.1382026-09-012026-09-10
A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
ATX-898, ATX-898, fulvestrant, ribociclib - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingAntares Therapeutics, Inc3432026-08-312026-10-16
Rash & Diarrhea Prophylaxis With Capivasertib
Capivasertib, Loperamide, Fulvestrant - Metastatic HR+/HER2- Breast Cancer
Phase 2RecruitingMaryam Lustberg1082026-08-152026-07-29
A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors
LAE118, Fulvestrant, Palbociclib - Patients With Advanced Solid Tumors
Phase 1Not yet recruitingLaekna Limited1502026-08-012026-08-26

Showing 20 of 489. Sign in to see all of them.

Conditions studied

Breast Neoplasms (344)  ·  Neoplasm Metastasis (42)  ·  Neoplasms (26)  ·  Ovarian Neoplasms (19)  ·  Carcinoma, Non-Small-Cell Lung (13)  ·  Endometrial Neoplasms (12)  ·  Hereditary Sensory and Autonomic Neuropathies (10)  ·  Prostatic Neoplasms (10)  ·  Triple Negative Breast Neoplasms (8)  ·  Breast Diseases (5)  ·  Carcinoma, Ovarian Epithelial (5)  ·  Colorectal Neoplasms (5)  ·  Multiple Endocrine Neoplasia Type 1 (5)  ·  Recurrence (5)  ·  Squamous Cell Carcinoma of Head and Neck (5)

Sponsors

AstraZeneca (36)  ·  Novartis Pharmaceuticals (27)  ·  Fudan University (17)  ·  Eli Lilly and Company (15)  ·  Pfizer (15)  ·  Hoffmann-La Roche (13)  ·  National Cancer Institute (NCI) (10)  ·  Memorial Sloan Kettering Cancer Center (7)  ·  Dana-Farber Cancer Institute (6)  ·  Genentech, Inc. (6)  ·  MedSIR (6)  ·  ImmunityBio, Inc. (5)  ·  M.D. Anderson Cancer Center (5)  ·  Mayo Clinic (5)  ·  Spanish Breast Cancer Research Group (5)

Countries

United States (267)  ·  China (110)  ·  Spain (96)  ·  France (86)  ·  United Kingdom (80)  ·  Italy (78)  ·  Germany (66)  ·  Canada (64)  ·  South Korea (61)  ·  Belgium (54)  ·  Australia (53)  ·  Taiwan (39)  ·  Argentina (38)  ·  Japan (38)  ·  Brazil (37)

Top investigators

Cynthia Ma (3)  ·  Sabino De Placido, MD (3)  ·  Anthony D Elias, MD (2)  ·  Antonio Llombart (2)  ·  Claudine Isaacs, MD (2)

Results publications

PMID 32385714, PMID 38439079, PMID 23902874, PMID 24919854, PMID 27269946, PMID 29522361, PMID 32001832, PMID 33149768, PMID 35181666, PMID 37597578, PMID 38937298, PMID 39177931, PMID 12954578, PMID 16505423, PMID 19153124, PMID 19239974, PMID 20632084, PMID 20938664, PMID 21792626, PMID 22123186, PMID 22418699, PMID 22444722, PMID 22853014, PMID 22999294, PMID 23497452, PMID 23798616, PMID 23801303, PMID 24327334, PMID 25002028, PMID 25348000, PMID 25524798, PMID 25691671, PMID 25892646, PMID 26030518, PMID 26171933, PMID 26371134, PMID 26947331, PMID 27029704, PMID 27155741, PMID 27315583, PMID 27368881, PMID 27908454, PMID 28045625, PMID 28183331, PMID 28274957, PMID 28540640, PMID 28576675, PMID 28580882, PMID 28586789, PMID 28652278

NIH funding

2023 (17), 2017 (11), 2025 (11), 2014 (9), 2015 (8), 2016 (8), 2019 (7), UM1CA186704 (3), 2004 (2), 2018 (2), N01CM00099 (2), N01CM62204 (2), U10CA031946 (2), U10CA180868 (2), 2005 (1)